Stage I - III Breast Cancer-Specific Survival (BCSS) Calculator

Age
<40
40-69
≥70
Tumor Grade ? Tumor Grade: Tumor grade is based on histologic grade which describes how abnormal the cancer cells and tissue look under a microscope and how quickly the cancer cells are likely to grow and spread. Grade I = (Low grade or well differentiated): Cells and tumor tissue look the most like normal cells and tissue. Grade II = (Intermediate grade or moderately differentiated):The tumor cells fall somewhere in between low and high grade. Grade III = (High grade or poorly differentiated): The cells and tissue look the most abnormal.
I
II
III
T ? Primary Tumor (T) based on AJCC 8th edition: TX Primary tumor cannot be assessed T0 No evidence of primary tumor Tis (DCIS) Ductal carcinoma in situ (DCIS) Tis (Paget) Paget disease of the nipple NOT associated with invasive carcinoma and/or carcinoma in situ (DCIS) in the underlying breast parenchyma. Carcinomas in the breast parenchyma associated with Paget disease are categorized based on the size and characteristics of the parenchymal disease, although the presence of Paget disease should still be noted. T1 Tumor ≤ 20 mm in greatest dimension T1mi Tumor ≤ 1 mm in greatest dimension T1a Tumor > 1 mm but ≤ 5 mm in greatest dimension (round any measurement from >1.0-1.9 mm to 2 mm) T1b Tumor > 5 mm but ≤ 10 mm in greatest dimension T1c Tumor > 10 mm but ≤ 20 mm in greatest dimension T2 Tumor > 20 mm but ≤ 50 mm in greatest dimension T3 Tumor > 50 mm in greatest dimension T4 Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4 T4a Extension to chest wall; invasion or adherence to pectoralis muscle in the absence of invasion of chest wall structures does not qualify as T4 T4b Ulceration and/or ipsilateral macroscopic satellite nodules and/or edema (including peau d’orange) of the skin, which do not meet the criteria for inflammatory carcinoma T4c Both T4a and T4b T4d Inflammatory carcinoma
N ? Pathologic Nodes (pN) based on AJCC 8th edition: pNX Regional lymph nodes cannot be assessed (eg, not removed for pathologic study or previously removed) pN0 No regional lymph node metastasis identified or ITCs only pN0(i+) ITCs only (malignant cell clusters no larger than 0.2 mm) in regional lymph node(s) pN0(mol+) Positive molecular findings by reverse transcriptase-polymerase chain reaction (RT-PCR); no ITCs detected pN1 Micrometastases; or metastases in 1-3 axillary lymph nodes and/or clinically negative internal mammary lymph nodes with micrometastases or macrometastases by sentinel lymph node biopsy pN1mi Micrometastases (approximately 200 cells, larger than 0.2 mm but none larger than 2.0 mm) pN1a Metastases in 1-3 axillary lymph nodes, at least one metastasis larger than 2.0 mm pN1b Metastases in ipsilateral internal mammary sentinel nodes, excluding ITCs pN1c pN1a and pN1b combined pN2 Metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases pN2a Metastases in 4-9 axillary lymph nodes (at least one tumor deposit larger than 2.0 mm) pN2b Metastases in clinically detected internal mammary lymph nodes with or without microscopic confirmation; with pathologically negative axillary lymph nodes pN3 Metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than 3 axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes pN3a Metastases in 10 or more axillary lymph nodes (at least one tumor deposit larger than 2.0 mm); or metastases to the infraclavicular (level III axillary lymph) nodes pN3b pN1a or pN2a in the presence of cN2b (positive internal mammary lymph nodes by imaging); or pN2a in the presence of pN1b pN3c Metastases in ipsilateral supraclavicular lymph nodes
M ? Distant Metastases (M) based on AJCC 8th edition: M0 No clinical or radiographic evidence of distant metastases cM0(i+) No clinical or radiographic evidence of distant metastases in the presence of tumor cells or and no deposits no greater than 0.2 mm detected microscopically or by using molecular techniques in circulating blood, bone marrow, or other nonreginal lymph node tissue in a patient without symptoms or signs of metastases M1 Distant metastases detected by clinical and radiographic means (cM) and/or histologically proven metastases larger than 0.2 mm (pM)
Pathologic Stage
ER Status (Estrogen Receptor) ? ER (Estrogen Receptor) Status: ER status measurement is based on ASCO-CAP guidelines: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer M. Elizabeth H. Hammond, Daniel F. Hayes, Mitch Dowsett, D. Craig Allred, Karen L. Hagerty, Sunil Badve, Patrick L. Fitzgibbons, Glenn Francis, Neil S. Goldstein, Malcolm Hayes, David G. Hicks, Susan Lester, Richard Love, Pamela B. Mangu, Lisa McShane, Keith Miller, C. Kent Osborne, Soonmyung Paik, Jane Perlmutter, Anthony Rhodes, Hironobu Sasano, Jared N. Schwartz, Fred C.G. Sweep, Sheila Taube, Emina Emilia Torlakovic, Paul Valenstein, Giuseppe Viale, Daniel Visscher, Thomas Wheeler, R. Bruce Williams, James L. Wittliff, and Antonio C. Wolff -- Journal of Clinical Oncology 2010 28:16, 2784-2795 See ASCO Guidelines link below.
Positive
Negative
Unknown
PR Status (Progesterone Receptor) ? PR (Progesterone Receptor) Status: PR status measurement is based on ASCO-CAP guidelines: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer M. Elizabeth H. Hammond, Daniel F. Hayes, Mitch Dowsett, D. Craig Allred, Karen L. Hagerty, Sunil Badve, Patrick L. Fitzgibbons, Glenn Francis, Neil S. Goldstein, Malcolm Hayes, David G. Hicks, Susan Lester, Richard Love, Pamela B. Mangu, Lisa McShane, Keith Miller, C. Kent Osborne, Soonmyung Paik, Jane Perlmutter, Anthony Rhodes, Hironobu Sasano, Jared N. Schwartz, Fred C.G. Sweep, Sheila Taube, Emina Emilia Torlakovic, Paul Valenstein, Giuseppe Viale, Daniel Visscher, Thomas Wheeler, R. Bruce Williams, James L. Wittliff, and Antonio C. Wolff -- Journal of Clinical Oncology 2010 28:16, 2784-2795 See ASCO Guidelines link below.
Positive
Negative
Unknown
HER2 Status (Human Epidermal Growth Factor Receptor-2) ? HER2 Status: HER2 status measurement is based on ASCO-CAP guidelines: Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update Antonio C. Wolff, M. Elizabeth H. Hammond, David G. Hicks, Mitch Dowsett, Lisa M. McShane, Kimberly H. Allison, Donald C. Allred, John M.S. Bartlett, Michael Bilous, Patrick Fitzgibbons, Wedad Hanna, Robert B. Jenkins, Pamela B. Mangu, Soonmyung Paik, Edith A. Perez, Michael F. Press, Patricia A. Spears, Gail H. Vance, Giuseppe Viale, and Daniel F. Hayes -- Journal of Clinical Oncology 2013 31:31, 3997-4013 See ASCO Guidelines link below.
Positive
Negative
Unknown
Hormone Receptor Status ? Hormone Receptor Status: Hormone receptor + (positive): defined as estrogen receptor positive OR progesterone receptor positive Hormone receptor - (negative): defined as estrogen receptor AND progesterone receptor negative
ASCO Guideline
for ER/PR IHC Testing
ASCO Guideline
for HER2 Testing
  Clear
This breast cancer survival prediction tool provides 5-year and 10-year estimates based on model derived from patients who underwent surgery as their 1st treatment from 1990 to 2016 at the University of Texas MD Anderson Cancer Center and received state-of the art treatment. The tool has been validated in an external dataset from the National Comprehensive Cancer Network (NCCN) database. The information provided here may be used as an aid in discussions between physicians and patients.